An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia

NCT00728195 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

498

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: JNJ-37822681
DRUG: JNJ-37822681
DRUG: JNJ-37822681
DRUG: Olanzapine
DRUG: Placebo

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.